Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
复制标题
免疫检查点阻断疗法的分子谱与年龄相关的差异
DOI：
10.3389/fimmu.2021.657575
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Song NH
中科院分区：
文献类型：
--
作者：
Zhang QJ;Luan JC;Song LB;Cong R;Ji CJ;Zhou X;Xia JD;Song NH
免疫检查点阻断（ICB）疗法显着改善了预后，并为癌症治疗显示出相当大的希望;然而，老年人和年轻人之间ICB治疗效果的差异尚不清楚。我们使用灵巧的方法分析了荟萃分析中纳入的研究，发现除了接受抗PD-1治疗的黑色素瘤患者外，疗效没有差异。同样，在某些癌症类型的老年患者中观察到更高的治疗反应率和更有利的预后（例如，黑色素瘤），数据来自已发表的ICB治疗临床试验。此外，我们全面比较了来自公开试验和癌症基因组图谱（TCGA）的老年和年轻患者之间的免疫治疗相关分子谱，并在几个独立的数据集中验证了这些发现。我们发现了一个不同的年龄偏见的免疫谱，包括肿瘤的性质（例如，肿瘤突变负荷）和免疫特征（例如，免疫细胞），在27种癌症类型的泛癌环境中。我们认为，ICB治疗效果可能因特定癌症类型而异，并由肿瘤内部特征和外部免疫微环境决定。考虑到老年患者在许多癌症类型中的高突变特性，调节免疫功能可能有利于老年人的免疫治疗，这需要进一步研究。
Immune checkpoint blockade (ICB) therapies have significantly improved the prognosis and shown considerable promise for cancer therapy; however, differences in ICB treatment efficacy between the elderly and young are unknown. We analyzed the studies enrolled in the meta-analysis using the deft approach, and found no difference in efficacy except melanoma patients receiving anti–PD-1 therapy. Similarly, higher treatment response rate and more favorable prognosis were observed in elderly patients in some cancer types (e.g., melanoma) with data from published ICB treatment clinical trials. In addition, we comprehensively compared immunotherapy-related molecular profiles between elderly and young patients from public trials and The Cancer Genome Atlas (TCGA), and validated these findings in several independent datasets. We discovered a divergent age-biased immune profiling, including the properties of tumors (e.g., tumor mutation load) and immune features (e.g., immune cells), in a pancancer setting across 27 cancer types. We believe that ICB treatment efficacy might vary depending on specific cancer types and be determined by both the tumor internal features and external immune microenvironment. Considering the high mutational properties in elderly patients in many cancer types, modulating immune function could be beneficial to immunotherapy in the elderly, which requires further investigation.
登录
查看更多内容
影响因子：
4.7
作者：
Kole, Sajal;Qadiri, Syed Shariq Nazir;Jung, Sung-Ju
通讯作者：
Jung, Sung-Ju
大黄鱼 (Larimichthys crocea) IL-2 同源物的分子克隆和生物活性
影响因子：
4.7
作者：
Mu, Pengfei;Wang, Yuhua;Chen, Xinhua
通讯作者：
Chen, Xinhua
影响因子：
3.7
作者：
Liu, Lu;Ge, Mingfeng;Wang, Guoliang
通讯作者：
Wang, Guoliang
DOI：
10.1038/nri2510
发表时间：
2009-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1084/jem.20051044
发表时间：
2005-11-07
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Hwang ES;Hong JH;Glimcher LH
通讯作者：
Glimcher LH